A Bayesian network meta‐analysis for acute thrombosis after lower extremity artery endovascular treatment

BACKGROUND Various endovascular treatment devices have been widely used in the lower extremity arterial disease (LEAD). Their patency efficiency for target lesions has been well studied and reported. Comparison of the risk of acute thrombosis events between the different endovascular treatment devices is unclear. AIMS To rank the risk of acute thrombosis events when bare metal stents (BMSs), covered stents (CSs), drug-eluting stents (DESs), drug-coated balloons (DCBs), and conventional percutaneous transluminal balloon angioplasty (PTA) are used to treat LEAD through Bayesian network meta-analysis. METHODS We performed a network meta-analysis of randomized controlled trials comparing the risk of 1-year postoperative acute thrombosis between BMSs, CSs, DESs, DCBs, and PTA for treating LEAD. Bayesian random models were used for pooled endovascular treatment modality comparisons. We ranked these treatment modalities via the Bayesian method according to their surface under the cumulative ranking curve (SUCRA) and estimated probabilities. RESULTS Nineteen studies (38 study arms; 2758 patients) were included. The Bayesian network ranking of treatments indicated that DCB had the lowest risk of acute thrombosis, PTA had the second-lowest risk of thrombosis, and CS, BMS, and DES had the highest risk of thrombosis. Regarding the treatment efficacy, the OR values of the loss of primary patency were significantly lower for DCB (OR = 0.44, 95% CI: 0.30-0.62), DES (OR = 0.36, 95% CI: 0.14-0.94), and CS (OR = 0.31, 95% CI: 0.18,0.56) than for PTA. When BMS was used as a reference, only the OR for CS was significantly lower (OR = 0.41, 95% CI = 0.21-0.82). Correspondingly, the Bayesian ranking of treatments from better to worse target lesion primary patency was CS, DES, DCB, BMS, and PTA. CONCLUSION With the available research evidence and according to the network analysis ranking, DES appears to have the highest risk of acute thrombosis and DCB appears to have the lowest risk.

[1]  P. Desgranges,et al.  A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial. , 2020, JACC. Cardiovascular interventions.

[2]  H. Schunkert,et al.  Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study) , 2019, European heart journal.

[3]  S. Holewijn,et al.  Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study , 2019, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[4]  Hong Wang,et al.  Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study Long Lesion Imaging Cohort , 2018, Circulation. Cardiovascular interventions.

[5]  P. Faries,et al.  Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease , 2017, Circulation.

[6]  M. Hadamitzky,et al.  ISAR‐PEBIS (Paclitaxel‐Eluting Balloon Versus Conventional Balloon Angioplasty for In‐Stent Restenosis of Superficial Femoral Artery): A Randomized Trial , 2017, Journal of the American Heart Association.

[7]  W. Matzek,et al.  Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial. , 2016, JACC. Cardiovascular interventions.

[8]  R. G. Statius van Eps,et al.  Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial , 2016, Circulation. Cardiovascular interventions.

[9]  Deepak L. Bhatt,et al.  Femoropopliteal Artery Stent Thrombosis: Report From the Excellence in Peripheral Artery Disease Registry , 2016, Circulation. Cardiovascular interventions.

[10]  D. Scheinert,et al.  Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial , 2015, Circulation.

[11]  D. Scheinert,et al.  Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapoplit , 2015, JACC. Cardiovascular interventions.

[12]  D. Scheinert,et al.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.

[13]  V. Aboyans,et al.  Epidemiology of peripheral artery disease. , 2015, Circulation research.

[14]  D. Scheinert,et al.  Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease , 2015, Circulation.

[15]  Katsumi Inoue,et al.  Pathological findings of late stent thrombosis after paclitaxel-eluting stent implantation for superficial femoral artery disease. , 2015, Journal of cardiology cases.

[16]  D. Scheinert,et al.  Superiority of Stent-Grafts for In-Stent Restenosis in the Superficial Femoral Artery , 2015, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[17]  S. Spiliopoulos,et al.  Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. , 2014, JACC. Cardiovascular interventions.

[18]  T. Rand,et al.  Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). , 2013, Journal of the American College of Cardiology.

[19]  A. Cannavale,et al.  Lower Limb Multilevel Treatment With Drug-Eluting Balloons: 6-Month Results From the DEBELLUM Randomized Trial , 2012, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[20]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[21]  T. Rand,et al.  Percutaneous transluminal angioplasty versus turbostatic carbon-coated stents in infrapopliteal arteries: InPeria II trial. , 2011, Radiology.

[22]  T. Stijnen,et al.  Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. , 2010, European heart journal.

[23]  F. Vermassen,et al.  Angioplasty or Primary Stenting for Infrapopliteal Lesions: Results of a Prospective Randomized Trial , 2010, CardioVascular and Interventional Radiology.

[24]  J. Lindeman,et al.  Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. , 2009, Journal of Vascular Surgery.

[25]  M. Dake,et al.  Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. , 2008, Journal of vascular and interventional radiology : JVIR.

[26]  A. Akhmedov,et al.  Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH2 Kinase Activation , 2006, Circulation research.

[27]  Johannes Lammer,et al.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. , 2006, The New England journal of medicine.

[28]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[29]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[30]  G. Sfyroeras,et al.  A network meta‐analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions , 2017, Journal of vascular surgery.

[31]  A. Cannavale,et al.  The "DEBELLUM"--lower limb multilevel treatment with drug eluting balloon--randomized trial: 1-year results. , 2014, The Journal of cardiovascular surgery.

[32]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.

[33]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[34]  J. Lammer,et al.  PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. , 2001, Journal of vascular and interventional radiology : JVIR.